Related Experiment Video
Updated: Jan 4, 2026
Induction and Testing of Hypoxia in Cell Culture
Published on: August 12, 2011
DUBs, Hypoxia, and Cancer
Daniela Mennerich1, Kateryna Kubaichuk1, Thomas Kietzmann2
1Faculty of Biochemistry and Molecular Medicine, University of Oulu, Oulu, 90570, Finland.
Abstract:
Alterations in protein ubiquitylation and hypoxia are commonly associated with cancer. Ubiquitylation is carried out by three sequentially acting ubiquitylating enzymes and can be opposed by deubiquitinases (DUBs), which have emerged as promising drug targets. Apart from protein localization and activity, ubiquitylation regulates degradation of proteins, among them hypoxia-inducible factors (HIFs). Thereby, various E3 ubiquitin ligases and DUBs regulate HIF abundance. Conversely, several E3s and DUBs are regulated by hypoxia. While hypoxia is a powerful HIF regulator, less is known about hypoxia-regulated DUBs and their impact on HIFs. Here, we review current knowledge about the relationship of E3s, DUBs, and hypoxia signaling. We also discuss the reciprocal regulation of DUBs by hypoxia and use of DUB-specific drugs in cancer.
Insights
Protein ubiquitylation and hypoxia are key in cancer. This review explores how deubiquitinases (DUBs) and hypoxia-inducible factors (HIFs) interact, highlighting DUBs as potential cancer drug targets.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Protein ubiquitylation and cellular hypoxia are frequently altered in cancer.
- Deubiquitinases (DUBs) counteract ubiquitylation and are emerging as significant therapeutic targets.
- Ubiquitylation regulates the degradation of key proteins, including hypoxia-inducible factors (HIFs).
Purpose of the Study:
- To review the intricate relationship between E3 ubiquitin ligases, DUBs, and hypoxia signaling pathways in cancer.
- To elucidate the less-understood regulation of DUBs by hypoxia and their subsequent impact on HIFs.
- To discuss the potential of DUB-specific drugs in cancer therapy.
Main Methods:
- Literature review of existing research on ubiquitylation, DUBs, hypoxia, and cancer.
- Analysis of the reciprocal regulatory mechanisms between hypoxia and DUBs.
- Examination of the role of DUBs in controlling HIF abundance and function.
Main Results:
- Hypoxia significantly influences HIF levels, partly through the action of E3 ligases and DUBs.
- Several E3 ligases and DUBs are themselves regulated by hypoxic conditions.
- The interplay between DUBs and hypoxia presents a complex regulatory network impacting cancer progression.
Conclusions:
- DUBs play a critical role in regulating HIFs, a key pathway in cancer.
- Understanding hypoxia-regulated DUBs is crucial for developing novel cancer treatments.
- Targeting DUBs offers a promising therapeutic strategy for cancers associated with altered hypoxia signaling.
Related Concept Videos
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
01:23Hypoxia
Types of Hypoxia
There are four primary types of hypoxia, each resulting from a different cause:
1. Anemic hypoxia: This type occurs due to insufficient oxygen delivery caused by a lack of red blood cells (RBCs) or RBCs with abnormal or...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:24Regulation of Angiogenesis and Blood Supply
01:27Oxygen Transport in the Blood
02:18Cancer